TRANSMITTAL

FORM

(to be used for all correspondence after initial filing)

RPTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

on Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

08/416,920 **Application Number Filing Date** April 21, 1995 **First Named Inventor** Miltenyi, S. 1644 **Group Art Unit**

		Exami	ner Name	Schwadron, R.			
Total Number of Pages in This Submission	6	Attorn	ey Docket Number	022370-000210US			
	ENCLO)SURES	(check all that apply)				
Fee Transmittal Form		ment Pap Application		After Allowance Communication to Group			
Fee Attached	Drawin	g(s)		Appeal Communication to Board of Appeals and Interferences			
Amendment / Response	Licensi	ng-relate	d Papers	Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)			
. After Final			Slip (PTO/SB/69) ying Petition	Proprietary Information			
Affidavits/declaration(s)		n to Conv onal App		Status Letter			
Extension of Time Request	Power of Attorney, Revocation Change of Correspondence Address			Other Enclosure(s) (please identify below):			
Express Abandonment Request	☐ Terminal Disclaimer ☐ Request for Refund		•	1) Return receipt postcard 2) PTO/SB/17 fee transmittal form 3) Six (6) references			
☐ Information Disclosure Statement	CD, Number of CD(s)		CD(s)	4) 41. (4) 1010101000			
Certified Copy of Priority Document(s)	Remarks The Commissioner is authorized to charge any add Deposit Account 20-1430.						
Response to Missing Parts/ Incomplete Application			j rotal number of page	as <u>aces no</u> t include cited relevances.			
Response to Missing Parts under 37 CFR 1.52 or 1.53							
SIGNA	SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT						
Firm Townsend and Townsend and Crew LLP							
and Randolph Ted Appl	e		Reg No.	36,429			
Signature .							
Date August 2004	Date August 3, 2004						

CERTIFICATE OF MAILING

Express Mail Label: EV 530884405 US. I hereby certify that this correspondence is being deposited with the United States Postal Service with "Express Mail Post Office to Address" service under 37 CFR 1.10 on this date August 17, 2004 and is addressed to: Commissioner for

Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below

Christopher R. Fitting Typed or printed name

Signature

Date

August 30, 2004

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 60294946 v1

	<u> </u>		P10/36/17 (10-03)
/	FEE TRANSMITTAL		Complete if Known
/		Application Number	09/416,920
3	AUG 3 0 2004 Of or FY 2004	Filing Date	April 21, 1995
\? !	Effective 100 /2003. Patent fees are subject to annual revision.	First Named Inventor	Miltenyi, S.
	Claims small entity status. See 37 CFR 1.27	Examiner Name	Schwadron, R.
		Art Unit	1644
	TOTAL AMOUNT OF PAYMENT (\$) 180	Attorney Docket No.	022370-000210US

	METHOD OF P	AYMENT (check all that apply)		FEE CALCULATION (continued)					
Check	Credit Card	Money Order Other Nor	9	3. ADD	ITIONAL I	EES			
Deposit Acc	_			Large	Entity	Small	Entity		
Deposit Account	20-143	<u> </u>		Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
Number	20-143			1051	130	2051	65	Surcharge - late filing fee or oath	
Deposit	L		_	1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet.	
Account	Townsend	and Townsend and Crew LLP		1053	130	1053	130	Non-English specification	
Name					2,520	1812	2,520	For filing a request for reexamination	
The Director is authorized to: (check all that apply) Charge fee(s) indicated below Credit any overpayments					920*	1804	920*	Requesting publication of SIR prior to Examiner action	
Charge any additional fee(s) or any underpayment of fee(s)					1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
Charge fee(s) indicated below, except for the filling fee to the above-identified deposit account.					110	2251	55	Extension for reply within first month	
to the above-iden		CALCULATION		1251 1252	420	2252	210	Extension for reply within second month	-
		CALCULATION		4'''	420		2.0		
	LING FEE			1253	950	2253	475	Extension for reply within third month	
	Small Entity	<u></u>		1254	1,480	2254	740	Extension for reply within fourth month	
	Fee Fee Code (\$)	Fee Description Fee P	ıid 	1255	2,010	2255	1,005	Extension for reply within fifth month	
1001 770	2001 385	Utility filing fee		1401	330	2401	165	Notice of Appeal	
	2002 170	Design filing fee		1402	330	2402	165	Filing a brief in support of an appeal	
[[2003 265	Plant filing fee		1403	290	2403	145	Request for oral hearing	
ł	2004 385 2005 80	Reissue filing fee Provisional filing fee		1451	1,510	1451	1,510	Petition to institute a public use proceeding	
·			_	1452	110	2452	55	Petition to revive – unavoidable	
	SUBTO	TAL (1) (\$)		1453	1,330	2453	665	Petition to revive - unintentional	
2. EXTRA CL	AIM FEES F	OR UTILITY AND REISSUE		1501	1,330	2501	665	Utility issue fee (or reissue)	
		Fee from ·		1502	480	2502	240	Design issue fee	
_	Ex	tra Claims below Fee Pa	<u>d</u>	1503	640	2503	320	Plant issue fee	
Total Claims		X		1460	130	1460	130	Petitions to the Commissioner	
Independent Claims	╡ <u>"</u> ͺ႞			1807	50	1807	50	Petitions related to provisional applications	
Multiple Dependent			=	1806	180	1806	180	Submission of Information Disclosure Stmt	180°
Dependent Large Entity	Small Entity	1		8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
Fee Fee Code (\$)	Fee Fee Code (\$)	Fee Description		1809	770	2809	385	Filing a submission after final rejection	
1202 18	2202 9	Claims in excess of 20		1		l		(37 CFR § 1.129(a))	
1201 86	2201 43	•		1810	770	2810	385	For each additional invention to be examined (37 CFR § 1.129(b))	
1203 290 1204 86	2203 145	** Reissue independent claims	paid	1801	770	2801	385	Request for Continued Examination (RCE)	
1205 18	2205	over original patent ** Reissue claims in excess of	20	1802	900	1802	900	Request for expedited examination of a design application	
	I SII	BTOTAL (2) (\$)	_	Other fe	e (specify)	·			
**or number previ		ter; For Reissues, see above					Fee Paid	SUBTOTAL (3) (\$)180	
		·		-l		-			

SUBMITTED BY	SUBMITTED BY Complete (if applicable)									
Name (Print/Type)	Randolph Ted Apple	Registration No. (Attorney/Agent)	36,429	Telephone	650-326-2400					
Signature	Roc			Date	August , 2004					

Attorney Docket No.: 022370-000210US



application of:

Miltenyi et al.

Application No.: 08/416,920

Filed: April 21, 1995

For: DIRECT SELECTION OF CELLS

BY SECRETION PRODUCT

Examiner: R. Schwadron

Art Unit: 1644

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37

CFR §1.97 and §1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The references cited on the attached PTO/SB/08A and PTO/SB/08B forms are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

References AB-AF describe the use of commercial embodiments of versions of the disclosed invention. Applicant also draws the following commonly owned copending applications to the attention of Examiner: No. 10/445,391 (entitled Direct Selection of Antigen - Specific T Cells, Compositions Obtained Thereby and Methods of Use Thereof) and No. 10/094,461 (entitled Direct Selection of Cells By Secretion Product).

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference

Miltenyi et al.

Application No.: 08/416,920

Page 2

should be made that the information and references cited are prior art merely because they are in this statement.

This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance. Please charge the IDS fee of \$180 to Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Randolph Ted Apple Reg. No. 36,429

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, Eighth Floor San Francisco, California 94111-3834

Tel: 650-326-2400 Fax: 650-326-2422

RTA:crf

60294770 v1

(32	AUG 3 0 2084	ر دو			PTO/SB/08A (08-03)
Substitu	ofor form 1449A/Po	ý			Complete if Known
	& TRADEWARK		•	Application Number	08/416,920
INFO	PRMATION	l DIS	SCLOSURE	Filing Date	April 21, 1995
STA	TEMENT B	BY A	PPLICANT	First Named Inventor	Miltenyi, S.
				Art Unit	1644
	(use as many she	eets as	necessary)	Examiner Name	Schwadron, R.
Sheet	1	of	2	Attorney Docket Number	022370-000210US

U.S. PATENT DOCUMENTS+									
		Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where				
Examiner Initials*	Cite No. ¹	Number Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
	AA	US-6,576,428	06-10-2003	Assenmacher et al.					
		· · · · · · · · · · · · · · · · · · ·							
	•								
					•				

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Initials* No.1			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited	Pages, Columns, Lines, Where Relevant Passages or Relevant	76		
ļ ——		Country Code ³	Number⁴	Kind Code ⁶ (if known)		Document	Figures Appear	 	
								 	
	<u> </u>								
	Ì								
			· ·			·····			

Examiner Signature	 Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04.

Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

Applicant is to place a check mark here if English language Translation is attached.

60294770 v1



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number 08/416,920

Filing Date April 21, 1995

First Named Inventor Miltenyi, S.

Art Unit 1644

Examiner Name Schwadron, R.

Attorney Docket Number 022370-000210US

(use as many sheets as necessary)

Sheet

2

NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item Cite (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), T² Examiner publisher, city and/or country where published. No.1 Initials * DENIZ et al., "Human NK1 and NK2 subsets determined by purification of IFN - \(\gamma \) secreting and IFN-\(\gamma \) AΒ nonsecreting NK cells," Eur. J. Immunol., 32:879-884 (2002). EDWARDS et al., "Microbial Recopgnition Via Toll-Like Receptor-Dependent and -Independent Pathways AC Determines the Cytokine Response of Murine Dendritic Cell Subsets to CD40 Triggering," J. Immunology, 169:3652-3660 (2002) HAYAKAWA et al., "Critical contribution of IFN-γ and NK cells, but not perforin-mediated cytotoxicity, to AD anti-metastatic effect of a α-galactosylceramide," Eur. J. Immunol., 31:1720-1727 (2001). HU-LI et al., "Regulation of Expression of IL-4 Alleles: Analysis Using a Chimeric GFP/IL-4 Gene," Immunity, ΑE 14:1-11 (2001). YANG et al., "Immunoregulatory Role of CD1d in the Hydrocarbon Oil-Induced Model of Lupus Nephritis," J. AF Immunology, 171:2142-2153 (2003).

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.